Demonstration of immunologic memory using serogroup C meningococcal glycoconjugate vaccine.

Demonstration of immunologic memory using serogroup C meningococcal glycoconjugate vaccine.

BACKGROUND: Studies of glycoconjugate vaccines have traditionally used an immune challenge with a plain polysaccharide vaccine to demonstrate immunologic memory. Plain polysaccharide vaccines are poorly immunogenic in children and can induce subsequent immunologic hyporesponsiveness. We therefore as...

Full description

Bibliographic Details
Main Authors:	Snape, MD, Maclennan, J, Lockhart, S, English, M, Yu, L, Moxon, R, Pollard, A
Format:	Journal article
Language:	English
Published:	2009

Similar Items

Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy
by: Pace, D, et al.
Published: (2016)

Immunologic memory with no detectable bactericidal antibody response to a first dose of meningococcal serogroup C conjugate vaccine at four years.
by: McVernon, J, et al.
Published: (2003)

Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X.
by: Micoli, F, et al.
Published: (2013)

Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization.
by: Snape, MD, et al.
Published: (2006)

Serogroup c meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization
by: Snape, M, et al.
Published: (2006)

Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
by: Perrett, K, et al.
Published: (2009)

Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial.
by: Read, R, et al.
Published: (2014)

Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: An observer-blind, phase 3 randomised clinical trial
by: Read, R, et al.
Published: (2014)

Will booster doses be required for serogroup B meningococcal vaccine?
by: McQuaid, F, et al.
Published: (2014)

Immunogenicity and immunologic memory of meningococcal C conjugate vaccine in premature infants.
by: Collins, C, et al.
Published: (2005)

Persistence of immunity following a booster dose of Haemophilus influenzae type B-Meningococcal serogroup C glycoconjugate vaccine: follow-up of a randomized controlled trial.
by: Khatami, A, et al.
Published: (2011)

Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination.
by: de Whalley, P, et al.
Published: (2013)

Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination
by: De Whalley, P, et al.
Published: (2013)

Serogroup B meningococcal vaccines-an unfinished story.
by: Sadarangani, M, et al.
Published: (2010)

No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales - Authors' reply
by: Snape, MD, et al.
Published: (2006)

Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease.
by: Pollard, A, et al.
Published: (2013)

Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.
by: Snape, MD, et al.
Published: (2008)

Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine.
by: Snape, MD, et al.
Published: (2005)

Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity.
by: Maiden, M, et al.
Published: (2008)

Plasma and memory B-cell kinetics in infants following a primary schedule of CRM 197-conjugated serogroup C meningococcal polysaccharide vaccine.
by: Kelly, D, et al.
Published: (2009)

Maintenance of immune response throughout childhood following serogroup C meningococcal conjugate vaccination in early childhood.
by: Khatami, A, et al.
Published: (2011)

CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells.
by: Kelly, D, et al.
Published: (2006)

Exonic single nucleotide polymorphisms within TLR3 associated with infant responses to serogroup C meningococcal conjugate vaccine
by: O'Connor, D, et al.
Published: (2014)

Challenges and progress in the development of a serogroup B meningococcal vaccine.
by: Lewis, S, et al.
Published: (2009)

Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine
by: De Whalley, P, et al.
Published: (2011)

Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine.
by: de Whalley, P, et al.
Published: (2011)

Exonic single nucleotide polymorphisms within TLR3 associated with infant responses to serogroup C meningococcal conjugate vaccine.
by: O'Connor, D, et al.
Published: (2014)

A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease.
by: Su, E, et al.
Published: (2011)

Emergence of serogroup X meningococcal disease in Africa: need for a vaccine.
by: Xie, O, et al.
Published: (2013)

Baseline polysaccharide-specific antibodies may not consistently inhibit booster antibody responses in infants to a serogroup C meningococcal protein-polysaccharide conjugate vaccine
by: Blanchard-Rohner, G, et al.
Published: (2012)

Baseline polysaccharide-specific antibodies may not consistently inhibit booster antibody responses in infants to a serogroup C meningococcal protein-polysaccharide conjugate vaccine.
by: Blanchard-Rohner, G, et al.
Published: (2012)

Immunization of HIV-infected adults in the UK with Haemophilus influenzae b/meningococcal C glycoconjugate and pneumococcal polysaccharide vaccines
by: MacLennan, C, et al.
Published: (2016)

Meningococcal polysaccharide-protein conjugate vaccines.
by: Snape, MD, et al.
Published: (2005)

Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study.
by: Snape, MD, et al.
Published: (2008)

Plasma and memory B-cell kinetics in infants following a primary schedule of CRM197-conjugated serogroup C meningococcal polysaccharide vaccine (vol 127, pg 134, 2009)
by: Kelly, D, et al.
Published: (2011)

The impact of the meningococcal serogroup C conjugate vaccine in Canada between 2002 and 2012.
by: Sadarangani, M, et al.
Published: (2014)

Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study
by: Snape, M, et al.
Published: (2008)

Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose.
by: Snape, MD, et al.
Published: (2013)

B cell memory to a serogroup C meningococcal conjugate vaccine in childhood and response to booster: little association with serum IgG antibody.
by: Perrett, K, et al.
Published: (2012)

Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial.
by: Snape, MD, et al.
Published: (2010)